Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Umecrine Mood, part of the Karolinska Development portfolio, has commenced dosing in the Phase I/II study of UC1010 for premenstrual dysphoric disorder (PMDD).
Subscribe to our email newsletter
A total of 120 individuals are expected to be included in the double-blind, multicenter study designed to assess the safety and efficacy profile of UC1010.
Umecrine Mood CEO Karin Ekberg said it is the first company to develop compounds that have demonstrated ability to reduce the activity of the breakdown product in healthy individuals.
"Now we take the next step to evaluate the safety and efficacy of our drug candidate in patients," Ekberg added.
Antidepressant drugs are primarily being used as current treatment options for PMDD.
Karolinska Development CEO Torbjörn Bjerke said, "There is no doubt that these women are in need of an effective and targeted treatment, nor that the health economic benefits of being able to help the patient group would be significant."